<DOC>
	<DOC>NCT00692289</DOC>
	<brief_summary>This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire</brief_summary>
	<brief_title>Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Provision of informed consent Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment. Allergy to substance of medication Preperimenopausal woman Woman not eligible for treatment</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Quality of Life</keyword>
</DOC>